{"id":"W3135563856","doi":"10.1016/j.jtocrr.2021.100157","title":"Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Boehringer Ingelheim; Pfizer Canada; AbbVie; Merck; AstraZeneca; Novartis; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Internal medicine; Alectinib; ALK inhibitor; Anaplastic lymphoma kinase; Oncology; Ceritinib; Lung cancer; Context (archaeology); Population; Hazard ratio; Brain metastasis; Gastroenterology; Cancer; Metastasis; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007263193,0.0003181888,0.0002750228,0.001169468,0.000590943,0.00114122,0.0007008897,0.0004975458,0.002179948],"category_scores_gemma":[0.002401677,0.0002687946,0.0005631018,0.002082072,0.0007162679,0.0005472072,0.0006874756,0.0006251706,0.0002166541],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003612725,"about_ca_system_score_gemma":0.002976728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3839788,"about_ca_topic_score_gemma":0.4986843,"domain_scores_codex":[0.9991043,0.0000976052,0.0000956667,0.0002019299,0.0002404432,0.0002600341],"domain_scores_gemma":[0.9980137,0.0001960947,0.0009157929,0.0001605993,0.0003524743,0.0003612079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001729079,0.00001284475,0.9984426,0.00001209695,0.00008551475,0.00003516309,0.00003517446,0.0001351644,0.00004517907,0.00002762845,0.0003836562,0.0006120633],"study_design_scores_gemma":[0.00001775606,0.00005196458,0.9984773,0.00001537838,0.00006368461,0.0001806898,0.0003147938,0.0003017758,0.00003576893,0.00002950462,0.0005024921,0.000008751312],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918697,0.0004874296,0.0001167005,0.00008013834,0.00001116825,0.00002430242,0.006630868,0.000007561121,0.0007721601],"genre_scores_gemma":[0.9955948,0.0001144551,0.00004792822,0.0000365753,0.000008685134,0.00001216178,0.003984145,0.000002115748,0.0001992047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3839788,"threshold_uncertainty_score":0.7634876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05235902605818746,"score_gpt":0.4677355556769182,"score_spread":0.4153765296187307,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}